All In Biotech

Drug Trial Radar · NCT05983939

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE_791 and Food Effect in Normal Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jun 26, 2023

Primary completion

Feb 1, 2024

Study completion Feb 1, 2024

Sponsor

Lead sponsor
Contineum TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE).

Conditions

  • Multiple Sclerosis

Interventions

  • PIPE-791Drug

    Single and multiple ascending oral doses of PIPE-791 tablets.

  • PlaceboDrug

    Single and multiple ascending oral doses of matching placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Treatment-Emergent Adverse Events (TEAE)Time frame: Baseline to 14 days post dosing for SAD cohorts and 14 days post dosing for MAD cohorts

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.